View in EDS

Oncolytic bacteria: past, present and future.

Saved in:
Bibliographic Details
Title: Oncolytic bacteria: past, present and future.
Authors: Rius-Rocabert, Sergio1, Llinares Pinel, Francisco1, Pozuelo, Maria Jose1, García, Antonia2, Nistal-Villan, Estanislao1 estanislao.nistalvillan@ceu.es
Source: FEMS Microbiology Letters. Jun2019, Vol. 366 Issue 12, pN.PAG-N.PAG. 1p. 6 Diagrams, 3 Charts.
Subjects: Reoviruses, BK virus, Bacteria
Abstract: More than a century ago, independent groups raised the possibility of using bacteria to selectively infect tumours. Such treatment induces an immune reaction that can cause tumour rejection and protect the patient against further recurrences. One of the first holistic approximations to use bacteria in cancer treatment was performed by William Coley, considered the father of immune-therapy, at the end of XIX century. Since then, many groups have used different bacteria to test their antitumour activity in animal models and patients. The basis for this reactivity implies that innate immune responses activated upon bacteria recognition, also react against the tumour. Different publications have addressed several aspects of oncolytic bacteria. In the present review, we will focus on revisiting the historical aspects using bacteria as oncolytic agents and how they led to the current clinical trials. In addition, we address the molecules present in oncolytic bacteria that induce specific toxic effects against the tumors as well as the activation of host immune responses in order to trigger antitumour immunity. Finally, we discuss future perspectives that could be considered in the different fields implicated in the implementation of this kind of therapy in order to improve the current use of bacteria as oncolytic agents. [ABSTRACT FROM AUTHOR]
Copyright of FEMS Microbiology Letters is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 137795495
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Oncolytic bacteria: past, present and future.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rius-Rocabert%2C+Sergio%22">Rius-Rocabert, Sergio</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Llinares Pinel%2C+Francisco%22">Llinares Pinel, Francisco</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Pozuelo%2C+Maria+Jose%22">Pozuelo, Maria Jose</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22García%2C+Antonia%22">García, Antonia</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Nistal-Villan%2C+Estanislao%22">Nistal-Villan, Estanislao</searchLink><relatesTo>1</relatesTo><i> estanislao.nistalvillan@ceu.es</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22FEMS+Microbiology+Letters%22">FEMS Microbiology Letters</searchLink>. Jun2019, Vol. 366 Issue 12, pN.PAG-N.PAG. 1p. 6 Diagrams, 3 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Reoviruses%22">Reoviruses</searchLink><br /><searchLink fieldCode="DE" term="%22BK+virus%22">BK virus</searchLink><br /><searchLink fieldCode="DE" term="%22Bacteria%22">Bacteria</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: More than a century ago, independent groups raised the possibility of using bacteria to selectively infect tumours. Such treatment induces an immune reaction that can cause tumour rejection and protect the patient against further recurrences. One of the first holistic approximations to use bacteria in cancer treatment was performed by William Coley, considered the father of immune-therapy, at the end of XIX century. Since then, many groups have used different bacteria to test their antitumour activity in animal models and patients. The basis for this reactivity implies that innate immune responses activated upon bacteria recognition, also react against the tumour. Different publications have addressed several aspects of oncolytic bacteria. In the present review, we will focus on revisiting the historical aspects using bacteria as oncolytic agents and how they led to the current clinical trials. In addition, we address the molecules present in oncolytic bacteria that induce specific toxic effects against the tumors as well as the activation of host immune responses in order to trigger antitumour immunity. Finally, we discuss future perspectives that could be considered in the different fields implicated in the implementation of this kind of therapy in order to improve the current use of bacteria as oncolytic agents. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of FEMS Microbiology Letters is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=137795495
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/femsle/fnz136
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: N.PAG
    Subjects:
      – SubjectFull: Reoviruses
        Type: general
      – SubjectFull: BK virus
        Type: general
      – SubjectFull: Bacteria
        Type: general
    Titles:
      – TitleFull: Oncolytic bacteria: past, present and future.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rius-Rocabert, Sergio
      – PersonEntity:
          Name:
            NameFull: Llinares Pinel, Francisco
      – PersonEntity:
          Name:
            NameFull: Pozuelo, Maria Jose
      – PersonEntity:
          Name:
            NameFull: García, Antonia
      – PersonEntity:
          Name:
            NameFull: Nistal-Villan, Estanislao
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 06
              Text: Jun2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 03781097
          Numbering:
            – Type: volume
              Value: 366
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: FEMS Microbiology Letters
              Type: main
ResultId 1